Recent grad charting her own path

Sarina Madhavan
GCB News

Recent grad charting her own path

By Alissa Kocer

As 3,000 first-year students begin preparing for their Duke career, recent graduate Sarina Madhavan has some advice for them: “Challenge what you think your passions are by seeking new experiences; be open to changes in your direction. And seek mentorship early on from those who will push, support and inspire you."

Madhavan graduated from Duke in the spring after completing an individualized major she titled “Medicine in the Genomic Era,” so she could investigate the social, policy and economic barriers to precision medicine in U.S. healthcare. “I wanted to explore the science and statistics behind precision medicine, the market forces driving tailored therapeutics, and the bioethical discourse surrounding clinical genomics,” Madhavan said.

During her time at Duke, Madhavan got involved in several research opportunities across the bench and bedside. In Charlie Gersbach’s lab, she worked toward the development of a CRISPR-based gene therapy for Duchenne’s Muscular Dystrophy. She also branched into health communications through her involvement with Peter Ubel’s team and worked to shed light on the ways that physicians engage in shared decision making with prostate cancer patients in real clinical encounters.

She culminated her undergraduate research career by co-leading the Enabling Precision Health and Medicine 2017-2018 Bass Connections team. Under the leadership of Drs. Susanne Haga and Lori Orlando, Madhavan and team sought to expand and improve the usability of the MeTree program, a patient-facing web-based family health history-driven risk assessment tool. The tool is being integrated into clinical practices to provide clinical decision support to patients and their primary care providers about risk levels and recommendations for risk management for 45 conditions.

“I love research because it sparks my continuous creativity,” Madhavan said, “while also teaching me the tools to achieve my core aspiration of using science and evidence to heal people.”

Madhavan is preparing for medical school at Harvard this fall and plans to specialize in oncology. She hopes to become a teaching physician-scientist at a large academic medical center. “I hope to improve the cost, quality and accessibility of national genomic screening efforts to facilitate preventative care across the country,” she said.

Related News

red blood cells

New Finding Could Unmask Blood Doping in Athletes

RNA changes mark old blood cells among new ones, foiling self-transfusions

Terrie Moffitt

Terrie Moffitt elected to National Academy of Medicine

Co-Director of Landmark Longitudinal Study in New Zealand

Greg Crawford, Kris Woods, Tim Reddy, and Charlie Gersbach

From Innovation to Impact

When four Duke researchers developed an innovative technique for exploring the non-coding genome—the 98 percent of our DNA that does not encode protein sequences, often called the genome’s “dark matter”—the implications were clear.